Cheng Zijia
ABSTRACT
Leukemia is known as a kind of "blood cancers" that is caused by the disorders of hematopoietic stem cells (HSCs). It is one of the most common cancers that spreads all around the world. Leukemia causes countless people's deaths every year, and people have been working on improving leukemia therapies very hard for years. The traditional therapies, including chemotherapy and bone marrow transplantation, may either cause harms to the patient himself/herself or cause strong or weak immune resistance so that people have always tried to find some better ways for leukemia therapy. In recent years, as the new immunotherapies develop, they're gradually used as cancer therapies. For example, Chimeric-antigen receptor T (CAR-T) cell therapy is already proved in several researches and is used for leukemia in these years. CAR-T is a targeted immunotherapy for cancers. It is comparatively very safe and effective and would cause the least resistance since all the CAR-T cells are originally developed from the patient's normal, healthy T cells. This review would mainly talk about the research progress of CAR-T cell therapy in recent years, give some directions and advices in the later discussion section.
- Juliusson, G. and R. Hough, Leukemia. Prog Tumor Res, 2016. 43: p. 87--100.Google Scholar
- Coombs, C.C. and S.P. Mathews, Acute promyelocytic leukemia and chronic lymphocytic leukemia diagnosed concurrently. Am J Hematol, 2018. 93(4): p. 595--596.Google Scholar
- Barrett, A.J., Acute myeloid leukaemia and the immune system: implications for immunotherapy. Br J Haematol, 2020. 188(1): p. 147--158.Google Scholar
- Wilkins, O., A.M. Keeler, and T.R. Flotte, CAR T-Cell Therapy: Progress and Prospects. Hum Gene Ther Methods, 2017. 28(2): p. 61--66.Google Scholar
- Ferlay, J., et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015. 136(5): p. E359--86.Google ScholarCross Ref
- Khazaei, Z., et al., Global Cancer Statistics 2018: Globocan Estimates of Incidence and Mortality Worldwide Stomach Cancers and Their Relationship with the Human Development Index (Hdi). World Cancer Research Journal, 2019. 6.Google Scholar
- Subklewe, M., M. von Bergwelt-Baildon, and A. Humpe, Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy. Transfus Med Hemother, 2019. 46(1): p. 15--24.Google Scholar
- Yanez, L., M. Sanchez-Escamilla, and M.A. Perales, CAR T Cell Toxicity: Current Management and Future Directions. Hemasphere, 2019. 3(2): p. e186.Google Scholar
- Ritchie, D.S., et al., Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther, 2013. 21(11): p. 2122--9.Google Scholar
- Morrison, C., CAR-T field booms as next-generation platforms attract big players. Nat Biotechnol, 2015. 33(6): p. 571--2.Google Scholar
- Sakoda, Y. and K. Tamada, [Development of cancer immunotherapy by next generation multi-targeting CAR-T cells]. Rinsho Ketsueki, 2014. 55(6): p. 651--6.Google Scholar
- Brentjens, R.J. and K.J. Curran, Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematology Am Soc Hematol Educ Program, 2012. 2012: p. 143--51.Google Scholar
- Scarfo, I. and M.V. Maus, Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer, 2017. 5: p. 28.Google Scholar
- Liu, D., J. Zhao, and Y. Song, Engineering switchable and programmable universal CARs for CAR T therapy. J Hematol Oncol, 2019. 12(1): p. 69.Google Scholar
- Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2020. CA Cancer J Clin, 2020. 70(1): p. 7--30.Google Scholar
- Assi, R., et al., Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol, 2018. 25(2): p. 136--145.Google Scholar
- Gill, S.I., How close are we to CAR T-cell therapy for AML? Best Practice & Research Clinical Haematology, 2019. 32(4).Google ScholarCross Ref
- Selheim, F., Targeted and Immune-Based Therapies for Acute Myeloid Leukemia: Inflammatory Signaling and Multiple Post-Translational Modifications. Curr Med Chem, 2019. 26(28): p. 5242--5243.Google Scholar
- Witkowski, M.T., et al., Immune-Based Therapies in Acute Leukemia. Trends Cancer, 2019. 5(10): p. 604--618.Google Scholar
- Schiattone, L., P. Ghia, and L. Scarfo, The evolving treatment landscape of chronic lymphocytic leukemia. Curr Opin Oncol, 2019. 31(6): p. 568--573.Google Scholar
- Acharya, U.H., et al., Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Rev Hematol, 2019. 12(3): p. 195--205.Google Scholar
- Teachey, D.T., et al., Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol, 2018. 15(4): p. 218.Google ScholarCross Ref
- Chen, F., et al., Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J Immunol Methods, 2016. 434: p. 1--8.Google ScholarCross Ref
- Hay, K.A., Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Br J Haematol, 2018. 183(3): p. 364--374.Google Scholar
Index Terms
- Chimeric-antigen Receptor T (CAR-T) Cell Therapy for Leukemia
Recommendations
Chimeric Antigen Receptor T-Cell Immunotherapy for Cancer
BIBE2020: Proceedings of the Fourth International Conference on Biological Information and Biomedical EngineeringCancer is a disease which causes a high death rate each year. The traditional therapies for treating cancers, for example, radiotherapy and chemotherapy, can cause the damage effect on both cancer cells and normal cells. Therefore, new immune therapies, ...
The risk factors for coagulation disorder of chimeric antigen receptor-T cell therapy in patients with hematological tumors: A systematic review and meta-analysis
Selected Papers From the 14th International Conference BIOMDLORE 2023BACKGROUND:Currently, the frequency of coagulation dysfunction associated with chimeric antigen receptor-T cell (Car-T) therapy cannot yet be determined.
OBJECTIVE:We performed a systematic ...
Comments